chloroquine and tofacitinib

chloroquine has been researched along with tofacitinib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Duan, Y; Han, J; Liao, C; Xie, Z; Yang, X	1
Bananis, E; Chen, C; Curtis, JR; Fan, H; Hirose, T; Lindsey, S; Mendelsohn, AM; Nduaka, CI; Tanaka, Y; Valdez, H; Wang, L; Winthrop, KL; Yamaoka, K	1

Reviews

1 review(s) available for chloroquine and tofacitinib

Article	Year
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. Journal of medicinal chemistry, 2021, 02-11, Volume: 64, Issue:3 Topics: Animals; Autoimmune Diseases; Drug Discovery; Humans; Models, Molecular; Protein Kinase Inhibitors; Small Molecule Libraries	2021

Other Studies

2 other study(ies) available for chloroquine and tofacitinib

Article	Year
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:10 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucocorticoids; Herpes Zoster; Humans; Incidence; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors	2017

Article

Year

A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.

Arthritis & rheumatology (Hoboken, N.J.), 2017, Volume: 69, Issue:10

Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucocorticoids; Herpes Zoster; Humans; Incidence; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors

2017